Wharton Business Group’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.96M | Buy |
290,727
+5,255
| +2% | +$108K | 0.25% | 51 |
|
|
2025
Q1 | $5.85M | Buy |
285,472
+14,855
| +5% | +$304K | 0.26% | 50 |
|
|
2024
Q4 | $6.12M | Sell |
270,617
-282
| -0.1% | -$6.38K | 0.28% | 52 |
|
|
2024
Q3 | $6.67M | Hold |
270,899
| – | – | 0.3% | 52 |
|
|
2024
Q2 | $6.26M | Buy |
270,899
+1,345
| +0.5% | +$31.1K | 0.32% | 51 |
|
|
2024
Q1 | $6.49M | Buy |
269,554
+68,890
| +34% | +$1.66M | 0.31% | 49 |
|
|
2023
Q4 | $4.62M | Sell |
200,664
-82,700
| -29% | -$1.9M | 0.23% | 54 |
|
|
2023
Q3 | $5.77M | Buy |
283,364
+20,014
| +8% | +$407K | 0.32% | 53 |
|
|
2023
Q2 | $6.15M | Sell |
263,350
-44,150
| -14% | -$1.03M | 0.41% | 44 |
|
|
2023
Q1 | $7.16M | Buy |
307,500
+152,195
| +98% | +$3.54M | 0.43% | 43 |
|
|
2022
Q4 | $3.91M | Sell |
155,305
-150,600
| -49% | -$3.79M | 0.23% | 59 |
|
|
2022
Q3 | $8.07M | Buy |
305,905
+6,030
| +2% | +$159K | 0.55% | 36 |
|
|
2022
Q2 | $8.67M | Buy |
299,875
+75,305
| +34% | +$2.18M | 0.57% | 36 |
|
|
2022
Q1 | $7.74M | Buy |
224,570
+86,435
| +63% | +$2.98M | 0.47% | 37 |
|
|
2021
Q4 | $6.05M | Sell |
138,135
-22,860
| -14% | -$1M | 0.37% | 44 |
|
|
2021
Q3 | $8.16M | Sell |
160,995
-1,895
| -1% | -$96.1K | 0.83% | 18 |
|
|
2021
Q2 | $8.48M | Buy |
162,890
+44,155
| +37% | +$2.3M | 0.66% | 31 |
|
|
2021
Q1 | $5.43M | Buy |
118,735
+97,625
| +462% | +$4.46M | 0.42% | 38 |
|
|
2020
Q4 | $970K | Sell |
21,110
-195
| -0.9% | -$8.96K | 0.08% | 60 |
|
|
2020
Q3 | $830K | Buy |
21,305
+3,355
| +19% | +$131K | 0.08% | 58 |
|
|
2020
Q2 | $682K | Buy |
+17,950
| New | +$682K | 0.07% | 61 |
|